Radiopharmaceuticals for Painful Bone Metastases: Perspective from Radiation Oncology

Journal of Supportive Oncology

Volumn 9, Issue 6, 2011, Pages 208-209

  Barnes, Elizabeth A ^a  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; RADIOISOTOPE; SAMARIUM; STRONTIUM;

BONE MARROW SUPPRESSION; BONE METASTASIS; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; DRUG SAFETY; DRUG UTILIZATION; EXTERNAL BEAM RADIOTHERAPY; HUMAN; NOTE; QUALITY OF LIFE; REPEAT PROCEDURE;

BONE NEOPLASMS; HUMANS; PAIN; RADIOPHARMACEUTICALS;

EID: 83455195239     PISSN: 15446794     EISSN: 1879596X     Source Type: Journal    
DOI: 10.1016/j.suponc.2011.06.006     Document Type: Note

References (4)

1. Damerla V., Packianathan S., Boerner P.S., et al. Recent developments in nuclear medicine in the management of bone metastases: a review and perspective. Am J Clin Oncol 2005, 28(5):513-520.
2. Lutz S., Berk L., Chang E., et al. American Society for Radiation Oncology (ASTRO). Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys 2011, 79(4):965-976.
3. Tu S.M., Millikan R.E., Mengistu B., et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 2001, 357(9253):336-341.
4. Single-fraction compared with multiple-fraction therapy in treating patients with previously irradiated painful bone metastases ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/NCT00080912.